Patent reform still pending, after six decades

FORT COLLINS – In developing vaccines and recombinant proteins to stave off infectious diseases and illnesses, Ventria Bioscience works inside miniscule manufacturing spaces: grains of rice and barley.

“The plant is essentially the factory that makes the medicine,´ said Ventria CEO Scott Deeter.

The plant-based technology enables the small, Fort Collins biotech company to develop products that are both cost-effective and affordable for production and distribution around the world. Within the competitive field of biopharmaceuticals, Ventria’s innovative system has relied on the U.S. patent program to protect its medicines, technologies and uses. To date, the company holds 23 patents, with…